Fasedienol (PH94B) - (PALISADE-2)

September 10, 2026: Vistagen (NASDAQ: VTGN) announced it will present Phase 3 subgroup data for fasedienol nasal spray at Psych Congress in New Orleans on September 17-18, 2026. The poster, “Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials,” is described as highlighting a positive efficacy signal in public speaking challenge study participants with very severe social anxiety disorder.

The presentation is poster number 230 and will be authored by Azmi Nasser, Michael R. Liebowitz, Aubrey Reid, Imogene Dunn, Eric Davis, Ross A. Baker, Angel Angelov, and Louis Monti.

The release also identifies Vistagen’s broader intranasal pherine pipeline: fasedienol for acute treatment of social anxiety disorder, itruvone for major depressive disorder, and refisolone for vasomotor symptoms due to menopause.